NCT03314857CompletedNot Applicable
Safety and Effectiveness of Edwards Lifesciences SAPIEN XT Transcatheter Heart Valve in the Chinese Population
Edwards Lifesciences3 sites in 1 country67 target enrollmentStarted: September 18, 2017Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 67
- Locations
- 3
- Primary Endpoint
- All-cause Mortality
Study Overview
Brief Summary
To evaluate the safety and effectiveness of the SAPIEN XT (Edwards Lifesciences, Irvine, California) transcatheter heart valve implantation (TAVI) in Chinese patients with symptomatic severe calcific aortic stenosis who are considered at high risk for surgical valve replacement.
Detailed Description
Edwards SAPIEN XT™ Transcatheter Heart Valve and NovaFlex+ delivery system will be used for this study.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 60 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects who are considered to be operable and high risk for surgical valve replacement: 8 ≤ STS Score ≤ 15 or 15 ≤ Logistic EuroSCORE ≤
- •If STS score is below 8 and/or Logistic EuroSCORE is below 15, patients should have other clinical or anatomical risk factors that would be considered high risk for surgery and documented by the heart team.
- •Severe symptomatic aortic stenosis requiring aortic valve replacement characterized by one or more of the following within 60 days prior to the index procedure: AVA < 0.8 cm2, Indexed AVA <0.5 cm2/m2, mean gradient > 40mmHg, or peak aortic jet velocity > 4.0m/sec.
- •NYHA Functional Class II or greater.
- •The study patient or the study patient's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the EC of the respective clinical site.
- •The study patient agrees to comply with all required post procedure follow-up visits.
Exclusion Criteria
- •Evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended treatment.
- •Aortic valve is a congenital unicuspid or is non-calcified.
- •Aortic valve is bicuspid and the patient is less than 60 years old, or the aortic valve is bicuspid with no raphe (Sievers classification type 0).
- •Anomalous coronary artery that would interfere with proper placement of the valve.
- •Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation >3+).
Outcomes
Primary Outcomes
All-cause Mortality
Time Frame: 30 days
All of the deaths that occurred in this population regardless of the cause.
Secondary Outcomes
- Cardiovascular Mortality(30 days)
- Number of Participates With a Stroke(30 days)
Investigators
Study Sites (3)
Loading locations...
Similar Trials
Completed
Not Applicable
China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese PopulationSymptomatic Aortic StenosisAortic RegurgitationAortic StenosisNCT03466918Edwards Lifesciences58
Completed
Not Applicable
Mitral Implantation of TRAnscatheter vaLvesMitral Valve DiseaseNCT02370511Mayra Guerrero91
Completed
Not Applicable
COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve DysfunctionPulmonary Valve StenosisPulmonary Valve InsufficiencyHeart Defects, CongenitalCongenital AbnormalitiesCardiovascular DiseasesHeart DiseasesNCT02987387Edwards Lifesciences57
Completed
Not Applicable
Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve/ The SAPIEN 3 StudyAortic Valve DiseaseNCT01808287Edwards Lifesciences250
Completed
Not Applicable
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High RiskSymptomatic Severe Aortic StenosisNCT01314313Edwards Lifesciences2,032